REG - PureTech Health PLC - PRTC's Seaport Files for Proposed Nasdaq IPO

Puretech HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM1579Aa&default-theme=true

RNS Number : 1579A  PureTech Health PLC  13 April 2026

13 April 2026

PureTech Health plc

 

PureTech Health Founded Entity Seaport Therapeutics Files Registration
Statement for Proposed Initial Public Offering

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a hub-and-spoke biotherapeutics company dedicated to giving life
to science and transforming innovation into value, today announced that its
Founded Entity, Seaport Therapeutics, Inc. ("Seaport"), has publicly filed a
Registration Statement on Form S-1 with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed initial public offering of shares of
its common stock. The timing, number of shares to be offered and the price
range for the offering have not yet been determined. The offering is subject
to market and other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of the
offering.

 

A registration statement relating to these securities has been filed with the
SEC but has not yet become effective. These securities may not be sold, nor
may offers to buy be accepted, prior to the time the registration statement
becomes effective. The offering will be made only by means of a prospectus.
When available, a copy of the preliminary prospectus may be obtained by
visiting the SEC's website at www.sec.gov or by contacting the offices of
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, by telephone at 1-866-471-2526, or by emailing
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone
at 866-803-9204, or by email at prospectus-eq_fi@jpmorganchase.com; Leerink
Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at
syndicate@leerink.com; Citigroup Global Markets Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at
1-800-831-9146; or Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720 or by emailing syndprospectus@stifel.com.

 

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to expectations
regarding Seaport's proposed initial public offering. The forward-looking
statements are based on current expectations and are subject to known and
unknown risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially from current
expectations, including, but not limited to, those risks, uncertainties and
other important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2024, filed with
the SEC and in our other regulatory filings. These forward-looking statements
are based on assumptions regarding the present and future business strategies
of the Company and the environment in which it will operate in the future.
Each forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we disclaim
any obligation to update or revise these forward-looking statements, whether
as a result of new information, future events or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFDEDEEMSEFL



            Copyright 2019 Regulatory News Service, all rights reserved